# US 2015/0104455 A1 · Methods and compositions for treating and diagnosing acute myocardial infarction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104455 A1
- Document ID: US20150104455A1
- Status: Published application
- Kind: A1
- Application number: 14/396,020
- Filed: 2013-04-25
- Published: 2015-04-16
- Earliest claimed: 2012-04-25
- Assignees: Genera Istrazivanja d.o.o.
- Applicants: GENERA ISTRAZIVANJA d.o.o.
- Inventors: Slobodan Vukicevic; Lovorka Grgurevic; Ivo Dumic-Cule
- Web page: https://patentgrep.com/patent/US20150104455A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and methods for treating and diagnosing acute myocardial infarction are described. The invention also provides a method of treating an individual to prevent or inhibit damage to myocardial tissue from an acute myocardial infarction comprising administering to the individual an antibody to BMP-1-3, or an antibody to BMP-1-4, or a combination of an antibody BMP-1-3 and an antibody to BMP-1-4 prior to AMI.

## Claims

### Claim 1

A method of treating acute myocardial infarction in an individual comprising administering to the individual an antibody to BMP-1-3, an antibody to BMP-1-4, or a combination of an antibody to BMP-1-3 and an antibody to BMP-1-4.

### Claim 2 (depends on 1)

The method according to claim 1, comprising administering to the individual an antibody to BMP-1-3.

### Claim 3 (depends on 1)

The method according to claim 1, comprising administering to the individual an antibody to BMP-1-4.

### Claim at position 4

4-7. (canceled)

### Claim 8

A method of determining whether an individual has sustained an acute myocardial infarction comprising assaying a blood sample previously obtained from the individual for the presence of BMP-1-4, wherein the presence of BMP-1-4 in the blood sample indicates that the individual has sustained an acute myocardial infarction.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the step of assaying the blood sample for the presence of BMP-1-4 comprises contacting the blood sample with a BMP-1-4 binding partner to form a binding complex between the binding partner and BMP-1-4 present in the blood sample.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the binding complex formed between the binding partner and BMP-1-4 present in the blood sample is detected by a detectable label associated with the BMP-1-4 binding partner.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the binding complex formed between the BMP-1-4 binding partner and BMP-1-4 present in the blood sample is detected by adding an antibody that binds to said BMP-1-4 binding partner or that binds to said BMP-1-4 present in said binding complex and detecting said antibody by a detectable label present on said antibody.

### Claim 12 (depends on 8, 9, 10, 11)

The method according to any one of claims 8-11, wherein the BMP-1-4 binding partner is an antibody that binds BMP-1-4.

### Claim 13

(canceled)

### Claim 14

An anti-BMP-1-3 antibody raised against the peptide immunogen R-Y-T-S-T-K-F-Q-D-T-L-H-S-R-K (amino acid residues 972-986 of SEQ ID NO:2).

### Claim 15

An anti-BMP-1-4 antibody raised against the peptide immunogen C-G-S-R-N-G-A-S-F-P-S-S-L-E-S-S-T-H-Q-A (SEQ ID NO:8).

### Claim 16

An anti-BMP-1-3 antibody produced by a hybridoma cell line that has accession no. DSM ACC3198.

### Claim 17

An anti-BMP-1-4 antibody produced by a hybridoma cell line that has accession no. DSM ACC3213.

### Claim 18

A method of treating an individual to prevent or inhibit damage to myocardial tissue from an acute myocardial infarction comprising administering to the individual an antibody to BMP-1-3, or an antibody to BMP-1-4, or a combination of an antibody to BMP-1-3 and an antibody to BMP-1-4 prior to an acute myocardial infarction.

### Claim 19 (depends on 18)

The method according to claim 18, comprising administering to the individual an antibody to BMP-1-3.

### Claim 20 (depends on 18)

The method according to claim 18, comprising administering to the individual an antibody to BMP-1-4.
